Alchemab Therapeutics

Biotech · Private

Platform that identifies novel drug targets by analyzing patient antibody repertoires

alchemab.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
0 granted · 8 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3240MICRORID TECHNOLOGIES, INC.——
3241CASCADE BIOTECHNOLOGY, INC.——
3242SEVIVO, LLC——
3243Alchemab Therapeutics——
3244Abdera Therapeutics——
3245HocusLocus Inc.——
3246DORIAN THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 8
  • Anti-complement Factor H Antibodiesapplication
  • Engineering Of Antigen-binding Proteinsapplication
  • ANTI-UNC5C Antibodiesapplication
  • Analysis Of Antigen-binding Proteinsapplication
  • ANTI-UNC5C Antibodies And Uses Thereofapplication
  • Anti-huntingtin Antibodiesapplication
  • Engineering Of Antigen-binding Proteinsapplication
  • ANTI-UNC5C Antibodiesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.